Basic Information | Post buying leads | Suppliers |
Name |
Quinine sulphate |
EINECS | 212-359-2 |
CAS No. | 804-63-7 | Density | 1.0807 (rough estimate) |
PSA | 128.57000 | LogP | 3.53910 |
Solubility | N/A | Melting Point |
235.2°C |
Formula | C40H50N4O8S | Boiling Point | 911.6 °C at 760 mmHg |
Molecular Weight | 746.925 | Flash Point | 505.1 °C |
Transport Information | N/A | Appearance | N/A |
Safety | 26-36 | Risk Codes | 36/37/38 |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
Quinine, sulfate (2:1) (salt) (8CI);130-95-0;QUININE;Legatrin;Quinine, sulfate (2:1) (salt);Quine;Biquinate (*Bisulfate heptathydrate*);QUININE SULFATE (2:1);Coco-Quinine;Quinine bisulfate;(8.alpha.,9R)-6-Methoxycinchonan-9-ol;(R)-[(4S,5S,7S)-5-ethenyl-1-azabicyclo[2.2.2]oct-7-yl]-(6-methoxyquinolin-4-yl)methanol;Quinine sulfate (VAN);Quinamm;Cinchonan-9-ol, 6-methoxy-, (8.alpha.,9R)-, sulfate;Aflukin;Quinine sulfate anhydrous;Quinsan (*2:1 Sulfate salt*), dihydrate;Quinine sulfate anhydrous [USAN];Quine (*2:1 Sulfate salt*, dihydrate);Cinchonan-9-ol,6'-methoxy-,(8R,9R)-,sulfate (2:1) (salt);Quinamm (*2:1 Sulfate salt*), dihydrate;Quinine hydrogen sulfate;Cinchonan-9-ol, 6-methoxy-, (8.alpha.,9R)-, sulfate (2:1) (salt);Dentojel (*Bisulfate heptathydrate*);(R)-[(5S,7S)-5-ethenyl-1-azabicyclo[2.2.2]oct-7-yl]-(6-methoxyquinolin-4-yl)methanol; sulfuric acid;Quinine, sulfate;Cinchonan-9-ol, 6-methoxy-, (8alpha,9R)-, sulfate (2:1) (salt);Quinoline alkaloid; |
Molecular structure of Quinine sulphate (CAS NO.804-63-7) is:
Product Name: Quinine sulphate
CAS Registry Number: 804-63-7
IUPAC Name: (R)-[(5R,7S)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanol; sulfuric acid
Molecular Weight: 746.912 [g/mol]
Molecular Formula: C40H50N4O8S
H-Bond Donor: 4
H-Bond Acceptor: 12
EINECS: 212-359-2
Flash Point: 505.1 °C
Enthalpy of Vaporization: 138.85 kJ/mol
Boiling Point: 911.6 °C at 760 mmHg
Product Categories: Organics
Other Registry Number: 57237-58-8
Quinine sulphate (CAS NO.804-63-7) is a quinoline derivatives,can bind with the parasite's DNA to form a complex that inhibits DNA replication and RNA transcription in order to inhibit parasite protein synthesis.The role is weaker than chloroquine. In addition,it can reduce parasite oxygen consumption ,resistant Plasmodium falciparum's phosphorylase metabolism to interfere its glucose metabolism.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
human | TDLo | oral | 4300ug/kg (4.3mg/kg) | PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BLOOD: AGRANULOCYTOSIS | British Medical Journal. Vol. 1, Pg. 605, 1977. |
man | TDLo | oral | 27mg/kg (27mg/kg) | SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SENSE ORGANS AND SPECIAL SENSES: TINNITUS: EAR GASTROINTESTINAL: NAUSEA OR VOMITING | British Medical Journal. Vol. 287, Pg. 1700, 1983. |
man | TDLo | oral | 129mg/kg (129mg/kg) | SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE | Human Toxicology. Vol. 3, Pg. 399, 1984. |
mouse | LDLo | oral | 800mg/kg (800mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 78, Pg. 159, 1943. | |
women | LDLo | oral | 126mg/kg/3W-I (126mg/kg) | CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" | British Journal of Clinical Practice. Vol. 46, Pg. 138, 1992. |
women | LDLo | oral | 220mg/kg (220mg/kg) | CARDIAC: OTHER CHANGES BLOOD: CHANGES IN SPLEEN LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA | Clinical Toxicology. Vol. 7, Pg. 129, 1974. |
women | TDLo | oral | 6500ug/kg (6.5mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS KIDNEY, URETER, AND BLADDER: INTERSTITIAL NEPHRITIS | American Journal of Kidney Diseases. Vol. 24, Pg. 211, 1994. |
women | TDLo | oral | 12mg/kg/1D-I (12mg/kg) | LIVER: "HEPATITIS, FIBROUS (CIRRHOSIS, POST-NECROTIC SCARRING)" | British Medical Journal. Vol. 286, Pg. 264, 1983. |
women | TDLo | oral | 45455ug/kg (45.455mg/kg) | SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE KIDNEY, URETER, AND BLADDER: RENAL FUNCTION TESTS DEPRESSED | Medical Journal of Australia. Vol. 141, Pg. 528, 1984. |
women | TDLo | oral | 80mg/kg (80mg/kg) | SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR GASTROINTESTINAL: NAUSEA OR VOMITING | British Medical Journal. Vol. 287, Pg. 1700, 1983. |
women | TDLo | oral | 110mg/kg (110mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR SENSE ORGANS AND SPECIAL SENSES: TINNITUS: EAR | American Journal of Emergency Medicine. Vol. 16, Pg. 214, 1998. |
women | TDLo | oral | 130mg/kg (130mg/kg) | SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | American Journal of Emergency Medicine. Vol. 9, Pg. 318, |
RIDADR: 1544
HazardClass: 6.1(b)
PackingGroup: III
Quinine sulphate , its cas register number is 804-63-7. It also can be called Cinchonan-9-ol, 6'-methoxy-, (8alpha,9R)-, sulfate (2:1) ; Cinchonan-9-ol, 6'-methoxy-, (8alpha,9R)-, sulfate (2:1) (salt) ; Quinine, sulfate (2:1) (salt) (8CI) ; Quinine sulfate anhydrous .